KOLEK, Vítězslav, Ivona GRYGÁRKOVÁ, Jiří CHALUPA, Leona KOUBKOVÁ, Jiřina ŠVECOVÁ, Jana SKŘIČKOVÁ, Lenka OSTŘÍŽKOVÁ and Dimka SIXTOVÁ. Oral vinorelbin in combination with cisplatin or carboplatin in adjutant chemotherapy of non-snall lung cancer: A prospective study of feasibility, tolerabity an 3-year surfoval. In Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer. 2011. ISSN 1556-0864.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Oral vinorelbin in combination with cisplatin or carboplatin in adjutant chemotherapy of non-snall lung cancer: A prospective study of feasibility, tolerabity an 3-year surfoval
Authors KOLEK, Vítězslav (203 Czech Republic, guarantor), Ivona GRYGÁRKOVÁ (203 Czech Republic), Jiří CHALUPA (203 Czech Republic), Leona KOUBKOVÁ (203 Czech Republic), Jiřina ŠVECOVÁ (203 Czech Republic), Jana SKŘIČKOVÁ (203 Czech Republic, belonging to the institution), Lenka OSTŘÍŽKOVÁ (203 Czech Republic) and Dimka SIXTOVÁ (203 Czech Republic).
Edition Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer, 2011.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.661
RIV identification code RIV/00216224:14110/11:00052780
Organization unit Faculty of Medicine
ISSN 1556-0864
Keywords in English oral vinorelbine; Adjuvant; chemotherapy; short time survival; NSCLC
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 15/9/2011 13:57.
Abstract
Adjuvant cisplatinum-based chemotherapy is recommended for routine use in patients with stages IIA, IIB, and IIIA of non smallcell lung cancer (NSCLC) after radical resection. Results in stage IB were not conclusive. Vinorelbine is a preferable associated drug in this indication and a randomized study proved the comparable effectiveness and tolerability of vinorelbine given both orally or intravenously (i.v.) in advanced NSCLC, meanwhile oral vinorelbine gives better comfort to patients.
PrintDisplayed: 27/9/2024 00:26